OneMedNet Enhances Data Discovery and Analytics with the Datavant Connect platform and Amazon Web Service (AWS) Clean Rooms
The healthcare industry has experienced a tremendous volume of health-related data generation—extending beyond patient interactions to include genomic sequencing, biomarker data, and more. In many ways, data has become the new oil, holding immense value for clinical and scientific advancement. However, like crude oil, this raw data must be refined—its fragmented and siloed nature continues to hinder accessibility and usability. As healthcare and life sciences organizations increasingly seek targeted, fit-for-purpose datasets, scalable and secure technological solutions have become essential to unlocking its full potential.
Leveraging AWS Clean Rooms, OneMedNet will offer sophisticated data partner assessment and discovery tools through the Datavant Connect platform, enabling secure collaboration environments without direct data movement or sharing of raw data. This 'no underlying data movement' approach significantly enhances data security and privacy, allowing for effective feasibility analyses between data sources and buyers.
These advancements facilitate faster identification and evaluation of relevant healthcare datasets, directly addressing the industry's strategic, privacy, and data handling challenges. By empowering healthcare organizations with precise, secure, and efficient data access, OneMedNet accelerates the generation of valuable insights and transformative outcomes.
'Much of today's healthcare data remains untapped due to complexity and interoperability issues,' continued Aaron Green. 'Datavant Connect powered by AWS Clean Rooms effectively removes these barriers, positioning OneMedNet as an indispensable partner for organizations aiming to fully harness the potential of healthcare data.'
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,400 healthcare sites through its iRWD™ platform. This isn't just data—it's the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet's proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at www.onemednet.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' or 'hopes' or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin's volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]
SOURCE: ONEMEDNET CORPORATION
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Peloton Interactive (PTON) Rallies to New High on Earnings Beat, Higher Price Targets
We recently published . Peloton Interactive, Inc. (NASDAQ:PTON) is one of the best-performing stocks on Friday. Peloton Interactive rallied for a second day on Friday, jumping 10.27 percent to close at $7.84 apiece, as investors cheered its earnings beat for the full fiscal year of 2025, alongside higher price targets from investment firms. In an updated report, Peloton Interactive, Inc. (NASDAQ:PTON) said it exceeded its full-year guidance on all key metrics, including revenue expectations of $2.455 billion to $2.470 billion, having posted actual revenues of $2.49 billion. The figure, however, was 7.8 percent lower than the $2.7 billion registered in the full fiscal year of 2024. Net loss also narrowed by 78 percent to $118.9 million from $551.9 million year-on-year. Copyright: 123mn / 123RF Stock Photo In the fourth quarter period, revenues decreased by 5.7 percent to $606.9 million from $643.6 million year-on-year, while a $21.6 million net income reversed a $30.5 million net loss in the same comparable period. Following the results, Goldman Sachs gave Peloton Interactive, Inc. (NASDAQ:PTON) increased its price target to $11.5 from $7 prior, while Deutsche Bank raised its target to $8.20 from $7.80 with a 'buy' recommendation. UBS maintained its price at $11 with a 'buy' recommendation, while Bernstein reaffirmed its price target of $7.5 with a 'market perform' rating. While we acknowledge the potential of PTON as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Kratos (KTOS) Jumps to New High on Higher Growth Outlook, Whopping Price Targets
We recently published . Kratos Defense & Security Solutions Inc. (NASDAQ:KTOS) is one of the best-performing stocks on Friday. Kratos Defense rallied to a new all-time high on Friday as investors cheered its higher growth outlook for full-year 2025, while taking heart from whopping price targets from investment firms. At intra-day trading, Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) touched a new 52-week high of $66.13, before a slight profit-taking pulled its share price lower to end the day just up by 8.12 percent at $63.88. Copyright: scanrail / 123RF Stock Photo In its updated report, the company raised its revenue growth forecast for the full year to $1.29 billion to $1.31 billion, from the $1.26 billion to $1.285 billion previously, as it expects to benefit from the US government's aggressive defense and security programs. In its market report, Raymond James raised its price target for the company to $80 from $40 previously, while maintaining a 'strong buy' recommendation' on expectations that it would grow its revenues to $2 billion over the next two years, reflecting an annual growth of more than 20 percent over the next five years, from only 10 percent at present. In a separate report, Royal Bank of Canada upgraded its price target for the company to $65 from $50 previously, while reaffirming an 'outperform' rating. In the second quarter of the year, Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) dropped its net income by 63 percent to $2.9 million from $7.9 million in the same period last year. Total revenues jumped by 17 percent to $351.5 million from $300.1 million year-on-year. While we acknowledge the potential of KTOS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
Yahoo
20 minutes ago
- Yahoo
Gilead Sciences (GILD) Touches New Record High as 10 Analysts Turn Bullish
We recently published . Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best-performing stocks on Friday. Gilead Sciences jumped to a new all-time high on Friday as investors cheered its impressive earnings performance in the second quarter of the year, alongside bullish ratings and price targets from 10 investment firms. Based on its updated report, Gilead Sciences, Inc. (NASDAQ:GILD) grew its attributable net income by 22.5 percent to $1.96 billion from $1.6 billion in the same period last year, while revenues inched up by 1.88 percent to $7.08 billion from $6.95 billion year-on-year. In the first half, the company swung to an attributable net income of $3.275 billion from a $2.5 billion net loss in the same comparable period. Revenues, however, were flat at $13.7 billion. Following the results, 10 analysts went bullish for Gilead Sciences, Inc. (NASDAQ:GILD), giving the latter 'buy' and 'overweight' ratings, alongside higher price targets. Among the highest to rate, Morgan Stanley raised its price target to $143 from $135; BofA Securities at $140 versus $126; BMO Capital with $130 versus $120; and JPMorgan at $135 versus $130. Other firms such as RBC, TD Cowen, Goldman Sachs, Baird, UBS, Truist Securities, and Oppenheimer, also assigned bullish ratings for the stock. For the full-year period, Gilead Sciences, Inc. (NASDAQ:GILD) increased its product sales growth forecast to a range of $28.3 billion to $28.7 billion, versus the $28.2 billion to $28.6 billion previously. Diluted EPS was also upgraded to $5.85 to $6.15 from the $5.65 to $6.05 prior. While we acknowledge the potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Sign in to access your portfolio
